AstraZeneca (AZN) vs Sanofi (SNY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
AstraZeneca (AZN) has outperformed Sanofi (SNY) over the past year, losing 7.0% versus a loss of 17.6%. Over five years, AZN leads with a +31.8% price change compared with -17.6% for SNY. AstraZeneca is the larger company by market cap ($246.87 billion vs $96.01 billion), about 2.6 times the size.
On valuation, Sanofi trades at a lower forward P/E (7.4x vs 13.8x for AstraZeneca). Sanofi offers the higher dividend yield (10.28% vs 2.03%).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AZN | SNY |
|---|---|---|
| Share price | $159.18 | $40.07 |
| Market cap | $246.87B | $96.01B |
| 1-day change | +0.25% | -0.40% |
| YTD return | -13.64% | -16.98% |
| 1-year return | -7.02% | -17.56% |
| 5-year return | +31.83% | -17.65% |
| P/E ratio (TTM) | 23.79 | 21.09 |
| Forward P/E | 13.76 | 7.42 |
| EPS (TTM) | $6.69 | $1.90 |
| Dividend yield | 2.03% | 10.28% |
| Annual dividend | $3.23 | $4.12 |
| Revenue (latest FY) | $58.74B | — |
| Revenue growth (YoY) | +8.63% | — |
| Net income (latest FY) | $10.22B | — |
| Gross margin | 81.90% | — |
| Operating margin | 23.40% | — |
| Net margin | 17.41% | — |
| 52-week high | $212.71 | $52.68 |
| 52-week low | $153.41 | $39.18 |
| Distance from 52-week high | -25.17% | -23.94% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +32.77% | +33.79% |
| Average volume | 3.37M | 2.87M |
| Shares outstanding | 1.55B | 2.40B |
| Employees | 96,100 | 74,846 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AstraZeneca is about 2.6 times larger than Sanofi by market value ($246.87B vs $96.01B).
- AZN has outperformed SNY by 10.5 percentage points over the past year.
- Sanofi offers a meaningfully higher dividend yield (10.28% vs 2.03%).
About AstraZeneca
AZN stock →AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Crestor, Andexxa, Onglyza, Symlin, XIGDUO XR, Atacand, Atacand HCT, Atacand Plus, Farxiga/Forxiga, Plendil, Modip, Splendil, Munobal, Flodil, Tenormin, Tenormine, Prenormine, Atenol, Zestril, Brilinta/Brilique, Komboglyze, Qtern, Wainua, Byetta, Lokelma, Seloken ZOK, Toprol-XL, Betaloc ZOK, XIGDUO, Accolate, Accoleit, Vanticon, Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Pulmicort Turbuhaler, Symbicort Turbuhaler, Airsupra, Bricanyl Turbuhaler, Fasenra, Rhinocort, Tezspire, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Saphnelo, Breztri Aerosphere, Duaklir Genuair, Pulmicort Respules, and Symbicort pMDI.
Health Care · Biotechnology: Pharmaceutical Preparations · 96,100 employees
About Sanofi
SNY stock →Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines.
Health Care · Biotechnology: Pharmaceutical Preparations · 74,846 employees
AZN vs SNY FAQ
Which is bigger, AstraZeneca or Sanofi?
AstraZeneca (AZN) is larger, with a market capitalization of $246.87B compared with $96.01B for Sanofi (SNY).
Which stock has performed better over the past year, AZN or SNY?
AZN returned -7.02% over the past 12 months, compared with -17.56% for SNY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AZN or SNY?
SNY has the lower trailing P/E at 21.1, versus 23.8 for AZN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, AstraZeneca or Sanofi?
Sanofi has the higher yield at 10.28%, compared with 2.03% for AstraZeneca.
Are AstraZeneca and Sanofi in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.